Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia

Sponsor
Peking University Third Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04265846
Collaborator
People's Hospital of Guangxi (Other)
140
1
29
4.8

Study Details

Study Description

Brief Summary

Compare postoperative Subjective and objective visual quality and economic efficiency of different Intraocular Lens(IOLs) implantation designed for the correction of presbyopia.

Condition or Disease Intervention/Treatment Phase
  • Device: bifocal IOL
  • Device: mix bifocal IOL
  • Device: trifocal IOL
  • Device: EDOF IOL
  • Device: different IOLs
  • Device: monofocal IOL
  • Device: monofocal IOL

Detailed Description

Compare postoperative Subjective and objective visual quality and economic efficiency of different Intraocular Lens Implantation designed for the correction of presbyopia.The subjects will undergo bilateral uneventful phacoemulsification and implantation of IOL.The subjects will be divided into several groups according to the type of the IOLs,including monofocal IOL group,monovision designed group ,bifocal IOL group, mix bifocal IOL group,trifocal IOL group,Exteded Depth of Focus(EDOF) IOL group and blend vision group. Compare the Subjective and objective visual quality and economic efficiency among these groups at 3 months postoperatively.

Study Design

Study Type:
Observational
Anticipated Enrollment :
140 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia
Actual Study Start Date :
May 31, 2020
Actual Primary Completion Date :
May 31, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
bifocal IOL group

The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.

Device: bifocal IOL
The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.

mix bifocal IOL group

The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally

Device: mix bifocal IOL
The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.

trifocal IOL group

The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.

Device: trifocal IOL
The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.

EDOF IOL group

The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.

Device: EDOF IOL
The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.

blend vision group

The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.

Device: different IOLs
The patients will undergo phacoemulsification and different IOLs implantation bilaterally.

monovision designed group

The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.

Device: monofocal IOL
The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.

monofocal IOL group

The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.

Device: monofocal IOL
The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.

Outcome Measures

Primary Outcome Measures

  1. monocular and binocular visual acuity [3 months postoperatively]

    uncorrected distance visual acuity (UCVA), intermediate visual acuity, near visual acuity will be measured at 5m, 80cm and 40cm respectively. All visual acuity measurements will be conducted under photopic conditions (85 cd/m2) and at 100% contrast

  2. economic efficiency [3 months postoperatively]

    economic efficiency was defined as the ratio of objective spectacle independence (UCVA better than 0.10 logMAR) and IOL price, then compare the economic efficiency among different groups.

Secondary Outcome Measures

  1. Binocular Contrast sensitivity [3 months postoperatively]

    Contrast sensitivity measures will be conducted binocularly, under photopic, mesopic (5 cd/m2), photopic with glare and mesopic with glare conditions, with the OPTEC 6500 contrast sensitivity test (Stereo Optical, USA). Contrast sensitivity will be evaluated at five spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree [cpd]). Patients will be allowed 5 minutes to adapt to each illumination level before testing.

  2. Binocular Defocus Curve [3 months postoperatively]

    Binocular defocus curves will be obtained in all patients, positioned at 5m under photopic (>85 cd/m 2 ) condition to measure the visual acuity with each defocus lens, representing the consecutive visual function of each eye. Negative lenses were added in 0.50 D steps and the visual acuity will be recorded for each type of defocus level. The procedure will be then repeated but with positive lenses. The range of defocus evaluated is from -4.00D to +2.00D.

  3. stereopsis [3 months postoperatively]

    distant stereopsis will be measured by block diagram of random-spot synoptophore, while near stereopsis will be measured by Yan's stereogram.

  4. Fusion function [3 months postoperatively]

    The fusion function of perception and movement (convergence and divergence)will be examined with a synoptophore.

  5. Subjective visual quality [3 months postoperatively]

    Using NEI-VFQ-25 questionnaire (Chinese version). Photic phenomena, spectacle independence, and satisfaction questionnaire.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with bilateral cataract

  • Regular corneal topography and Preoperative corneal astigmatism ≤ 0.75 Diopter

Exclusion Criteria:
  • Pregnant or nursing women

  • In the presence of other ocular diseases that may affect the stability of the lens capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, Marfan syndrome, etc.)

  • Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)

  • History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerv atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis.

  • Patients with history of ocular trauma or prior ocular surgery including refractive procedures

  • postoperative visual acuity of worse than 0.2 logMAR in any eye

  • Patients using systemic or ocular medication that affect visual acuity.

  • Patients participating in other clinical trials during the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100191

Sponsors and Collaborators

  • Peking University Third Hospital
  • People's Hospital of Guangxi

Investigators

  • Study Director: Qi Hong, PhD,MD, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04265846
Other Study ID Numbers:
  • 20191129
First Posted:
Feb 12, 2020
Last Update Posted:
Aug 12, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2022